Cancer Cell (journal)

Last updated

History

Cancer Cell was launched in 2002 with the publication of its inaugural issue on February 1, 2002. In an Editorial published in this first issue, Editor-in-Chief Mariana Resnicoff introduced Cancer Cell as "An exciting forum for cancer research". [3] Following in the footsteps of the Cell Press flagship journal Cell, the goal of Cancer Cell was to publish cutting-edge findings in cancer research and to provide great author service by having a team of dedicated scientific editors that hold the highest standards of excellence, editorial consistency, and author service. Li-Kuo Su became Editor-in-Chief in 2003 and is recognized for promoting the journal's growth and establishing it as one of the most reputable cancer research journals. He retired from his editorial activities in 2019. Steve Mao became Cancer Cell's Editor-in-Chief in 2020 after serving as senior editor at Cell and Science.

Changing for a better future editorial

In the April 2020 special issue of Cancer Cell, Steve Mao published the editorial "Changing for a Better Future" [4] delineating his views for the journal. This Editorial reiterated the journal's commitment to scientific excellence and introduced key changes. While Cancer Cell is traditionally considered a journal interested in strong mechanistic studies, the Editorial highlights its interest in translational and clinical studies, as well in discovery papers that scientifically sound and conceptually bold. In line with the Cell Press rebranding strategy launched in 2020, [5] Steve Mao vowed to continue publishing "Science that Inspires". The Editorial also states the editors' commitment to increase communication with its scientific community and authors, as well as to work with authors to improve the revision process of manuscripts under consideration.

Diversity and inclusion efforts

In 2020, Cancer Cell made a number of changes to increase diversity and inclusion of underrepresented minorities in cancer research and oncology. In June 2020, the journal announced the new members of its advisory board (previously editorial board), which includes a higher representation of female scientists (>40%) and physicians (~50%) and higher geographical and ethnic diversity. [6] That same month, the Cell Editorial Team published the editorial "Science has a racism problem", [6] acknowledging the underrepresentation of Black scientists in STEM in the wake of the murders of George Floyd, Breonna Taylor, and Ahmaud Arbery. These events, in conjunction with the anti-immigration policies of the Trump administration in the U.S., led to a Summer of social reckoning in the scientific community. Cancer Cell joined the cancer research and oncology communities and their call for action and change by dedicating its September 2020 issue to the importance of diversity and immigration in cancer research in the U.S. and publishing a series of opinion pieces by scientists and clinicians that represent several minorities (immigrants, Black, Latinx, LGBTQ) and their allies. [7] [8] [9] The journal has also published several articles that address ethnic health disparities and aim to increase the representation of non-Caucasian populations in cancer research and oncology. [10] [11] [12] [13] [14]

As a part of Cell Press, Cancer Cell has supported Black in Cancer and the #BlackInCancerWeek campaign on Twitter. The journal also participated in the creation of the "Rising Black Scientists Award", a cash award granted to one undergraduate student and one graduate student or postdoctoral trainee "meant to break down barriers and create opportunities by providing funds to support professional development". [15]

In January 2021, Cell Press introduced the Inclusion and Diversity Statement, in which authors may choose to disclose information related to how they are increasing their effort to promote genetic diversity in their study subjects, participation of minorities, and balancing gender representation, to name a few. [16]

Editorial process

Articles submitted to Cancer Cell are assigned to an in-house, professional scientific editor (handling editor). The handling editor reads the full manuscript, evaluates the relevant literature, and leads the editorial discussion with the rest of the editorial team to make a decision on how to proceed with the paper. Advisory Board Members and other experts may be confidentially contacted at this point to ask for their professional opinion to facilitate the initial decision making. Initial decisions are usually made within 5–7 days. If a paper is selected for peer review, the handling editor invites 3-4 reviewers whose areas of expertise cover different aspects of the paper. Reviewers submit their comments and recommendation within two weeks. After review, the handling editor evaluates the reviewers' comments, discusses them with the editorial team, and makes a decision on the paper. If a manuscript is invited to revise, the handling editor may communicate with the authors to agree on the revision plan and deadlines for resubmission. Once the revised manuscript is submitted, the handling editor may request additional feedback from the reviewers. Cancer Cell typically only allows for one round of major revisions for its articles. If the article is deemed suitable for publication in Cancer Cell, the handling editor will work with the authors to ensure the paper complies with the journal's format and guidelines, and that it communicates results clearly and accurately. Only after all the requirements are met will a paper be formally accepted for publication.[ citation needed ]

Other Scientific activities

Cancer Cell editors are involved in a diverse array of activities at Cell Press besides manuscript handling, such as organizing Cell Symposia, Webinars, and Cell Press Selections. Editors also attend national and international cancer research and oncology meetings, conduct site visits, and participate in career panels to interact with the scientific and medical community, as well as with students and trainees.[ citation needed ]

Related Research Articles

Scientific misconduct is the violation of the standard codes of scholarly conduct and ethical behavior in the publication of professional scientific research.

Cancer research is research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure.

<i>Medical Hypotheses</i> Academic journal

Medical Hypotheses is a not-conventionally-peer-reviewed medical journal published by Elsevier. It was originally intended as a forum for unconventional ideas without the traditional filter of scientific peer review, "as long as are coherent and clearly expressed" in order to "foster the diversity and debate upon which the scientific process thrives." The publication of papers on AIDS denialism led to calls to remove it from PubMed, the United States National Library of Medicine online journal database. Following the AIDS papers controversy, Elsevier forced a change in the journal's leadership. In June 2010, Elsevier announced that "submitted manuscripts will be reviewed by the Editor and external reviewers to ensure their scientific merit".

The Cancer Genome Atlas (TCGA) is a project to catalogue the genetic mutations responsible for cancer using genome sequencing and bioinformatics. The overarching goal was to apply high-throughput genome analysis techniques to improve the ability to diagnose, treat, and prevent cancer through a better understanding of the genetic basis of the disease.

<span class="mw-page-title-main">MTA3</span> Protein-coding gene in the species Homo sapiens

Metastasis-associated protein MTA3 is a protein that in humans is encoded by the MTA3 gene. MTA3 protein localizes in the nucleus as well as in other cellular compartments MTA3 is a component of the nucleosome remodeling and deacetylate (NuRD) complex and participates in gene expression. The expression pattern of MTA3 is opposite to that of MTA1 and MTA2 during mammary gland tumorigenesis. However, MTA3 is also overexpressed in a variety of human cancers.

Carlo Maria Croce is an Italian–American professor of medicine at Ohio State University, specializing in oncology and the molecular mechanisms underlying cancer. Croce and his research have attracted public attention because of multiple allegations of scientific misconduct.

<span class="mw-page-title-main">Ming-Ming Zhou</span>

Ming-Ming Zhou is an American scientist who focuses on structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold, Golden Lamport Professor, and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences.

Scientific Reports is a peer-reviewed open-access scientific mega journal published by Nature Portfolio, covering all areas of the natural sciences. The journal was established in 2011. The journal states that their aim is to assess solely the scientific validity of a submitted paper, rather than its perceived importance, significance, or impact.

Scholarly peer review or academic peer review is the process of having a draft version of a researcher's methods and findings reviewed by experts in the same field. Peer review is widely used for helping the academic publisher decide whether the work should be accepted, considered acceptable with revisions, or rejected for official publication in an academic journal, a monograph or in the proceedings of an academic conference. If the identities of authors are not revealed to each other, the procedure is called dual-anonymous peer review.

Gopal Chandra Kundu is an Indian cell and cancer biologist and a Senior Scientist (Scientist-G) at National Centre for Cell Science. He is known for his contributions towards the understanding the mechanism of cancer progression in breast, melanoma and other cancers and development of novel therapeutic targets and target-based therapy in cancers.

Frontiers Media SA is a publisher of peer-reviewed, open access, scientific journals currently active in science, technology, and medicine. It was founded in 2007 by Kamila and Henry Markram. Frontiers is based in Lausanne, Switzerland, with other offices in London, Madrid, Seattle and Brussels. In 2022, Frontiers employed more than 1,400 people, across 14 countries. All Frontiers journals are published under a Creative Commons Attribution License.

<span class="mw-page-title-main">Demetrios Spandidos</span> Greek virologist and cancer researcher (born 1947)

Demetrios A. Spandidos is a Greek virologist and cancer researcher. He is an emeritus professor at the University of Crete where he was professor of virology from 1989 till 2015. He is also the founder of Spandidos Publications and the editor-in-chief of all eight of its journals.

Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles.

<span class="mw-page-title-main">Harvey Chochinov</span> Canadian academic and psychiatrist

Harvey Max Chochinov is a Canadian academic and psychiatrist from Winnipeg, Canada. He is a leading authority on the emotional dimensions of end-of-life, and on supportive and palliative care. He is a Distinguished Professor of Psychiatry at the University of Manitoba and a Senior Scientist at CancerCare Manitoba Research Institute.

<span class="mw-page-title-main">He Jiankui affair</span> 2018 scientific and bioethical controversy

The He Jiankui affair is a scientific and bioethical controversy concerning the use of genome editing following its first use on humans by Chinese scientist He Jiankui, who edited the genomes of human embryos in 2018. He became widely known on 26 November 2018 after he announced that he had created the first human genetically edited babies. He was listed in the Time's 100 most influential people of 2019. The affair led to ethical and legal controversies, resulting in the indictment of He and two of his collaborators, Zhang Renli and Qin Jinzhou. He eventually received widespread international condemnation.

<span class="mw-page-title-main">UK Coronavirus Cancer Monitoring Project</span>

The UK Coronavirus Cancer Programme or UKCCP is one of the longest running UK pandemic research programmes to safeguard, monitor and protect individuals living with cancer from COVID-19 across the United Kingdom.

<span class="mw-page-title-main">Dan Theodorescu</span>

Dan Theodorescu is an American physician and academic. He is the Director of the Samuel Oschin Comprehensive Cancer Institute at the Cedars-Sinai Medical Center and leader of Cedars-Sinai CANCER. From 2010 until 2018, Theodorescu was Director of the University of Colorado Cancer Center and a professor of Surgery-Urology. He has been appointed Paul Mellon Chair at the University of Virginia and Paul Bunn Chair and Distinguished University Professor at the University of Colorado.

Karen E. Knudsen is Chief Executive Officer of American Cancer Society and its advocacy affiliate the American Cancer Society Cancer Action Network. She is the first woman to hold that position in either organization.

<span class="mw-page-title-main">Alberto Bardelli</span> Italian geneticist

Alberto Bardelli is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology, University of Turin and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology.

References

  1. ↑ "Addendum to the cOAlition S Guidance on the Implementation of Plan S | Plan S". www.coalition-s.org.
  2. ↑ "Elsevier expands Open Access options for Cell Press Journals from January 2021". www.elsevier.com.
  3. ↑ Resnicoff, Mariana (February 2002). "An exciting forum for cancer research". Cancer Cell. 1 (1): 1–2. doi: 10.1016/S1535-6108(02)00019-3 .
  4. ↑ Mao, Steve (April 2020). "Changing for a Better Future". Cancer Cell. 37 (4): 423. doi: 10.1016/j.ccell.2020.03.019 . PMID   32289264.
  5. ↑ The Cell Press Team (29 February 2020). "Science that Inspires". Heliyon. 6 (2): e03362. doi:10.1016/j.heliyon.2020.e03362. PMC   7052054 . PMID   32140576.
  6. 1 2 "Editorial Board: Cancer Cell". www.cell.com.
  7. ↑ Merad, Miriam; Posey, Avery D.; Olivero, Ofelia; Singh, Pankaj K.; Mouneimne, Ghassan; Li, Lingyin; Wallace, LaShanale M.; Hayes, Tikvah K. (September 2020). "Diversity Is a Strength of Cancer Research in the U.S." Cancer Cell. 38 (3): 297–300. doi: 10.1016/j.ccell.2020.08.018 . PMC   7489360 . PMID   32931736.
  8. ↑ Morin, Pat J.; Wirtz, Denis; Weeraratna, Ashani T. (September 2020). "Completing the Great Unfinished Symphony of Cancer Together: The Importance of Immigrants in Cancer Research". Cancer Cell. 38 (3): 301–305. doi: 10.1016/j.ccell.2020.08.017 . PMC   7489249 . PMID   32931737.
  9. ↑ Aifantis, Iannis; Neel, Benjamin G. (September 2020). "U.S. Biomedical Research Needs More Immigrant Scientists, Not Fewer!". Cancer Cell. 38 (3): 308. doi: 10.1016/j.ccell.2020.08.010 . PMC   7489325 . PMID   32931738.
  10. ↑ Jiang, Yi-Zhou; Ma, Ding; Suo, Chen; Shi, Jinxiu; Xue, Mengzhu; Hu, Xin; Xiao, Yi; Yu, Ke-Da; Liu, Yi-Rong; Yu, Ying; Zheng, Yuanting; Li, Xiangnan; Zhang, Chenhui; Hu, Pengchen; Zhang, Jing; Hua, Qi; Zhang, Jiyang; Hou, Wanwan; Ren, Luyao; Bao, Ding; Li, Bingying; Yang, Jingcheng; Yao, Ling; Zuo, Wen-Jia; Zhao, Shen; Gong, Yue; Ren, Yi-Xing; Zhao, Ya-Xin; Yang, Yun-Song; Niu, Zhenmin; Cao, Zhi-Gang; Stover, Daniel G.; Verschraegen, Claire; Kaklamani, Virginia; Daemen, Anneleen; Benson, John R.; Takabe, Kazuaki; Bai, Fan; Li, Da-Qiang; Wang, Peng; Shi, Leming; Huang, Wei; Shao, Zhi-Ming (March 2019). "Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies". Cancer Cell. 35 (3): 428–440.e5. doi: 10.1016/j.ccell.2019.02.001 . PMID   30853353.
  11. ↑ Carrot-Zhang, Jian; Chambwe, Nyasha; Damrauer, Jeffrey S.; Knijnenburg, Theo A.; Robertson, A. Gordon; Yau, Christina; Zhou, Wanding; Berger, Ashton C.; Huang, Kuan-lin; Newberg, Justin Y.; Mashl, R. Jay; Romanel, Alessandro; Sayaman, Rosalyn W.; Demichelis, Francesca; Felau, Ina; Frampton, Garrett M.; Han, Seunghun; Hoadley, Katherine A.; Kemal, Anab; Laird, Peter W.; Lazar, Alexander J.; Le, Xiuning; Oak, Ninad; Shen, Hui; Wong, Christopher K.; Zenklusen, Jean C.; Ziv, Elad; Cherniack, Andrew D.; Beroukhim, Rameen; Aguet, Francois; Ding, Li; Demchok, John A.; Mensah, Michael K.A.; Caesar-Johnson, Samantha; Tarnuzzer, Roy; Wang, Zhining; Yang, Liming; Alfoldi, Jessica; Karczewski, Konrad J.; MacArthur, Daniel G.; Meyerson, Matthew; Benz, Christopher; Stuart, Joshua M. (May 2020). "Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer". Cancer Cell. 37 (5): 639–654.e6. doi: 10.1016/j.ccell.2020.04.012 . PMC   7328015 . PMID   32396860.
  12. ↑ Whisenant, Jennifer G.; Trama, Annalisa; Torri, Valter; De Toma, Alessandro; Viscardi, Giuseppe; Cortellini, Alessio; Michielin, Olivier; Barlesi, Fabrice; Dingemans, Anne-Marie C.; Van Meerbeeck, Jan; Pancaldi, Vera; Soo, Ross A.; Leighl, Natasha B.; Peters, Solange; Wakelee, Heather; Garassino, Marina Chiara; Horn, Leora (June 2020). "TERAVOLT: Thoracic Cancers International COVID-19 Collaboration". Cancer Cell. 37 (6): 742–745. doi: 10.1016/j.ccell.2020.05.008 . PMC   7229923 . PMID   32425702.
  13. ↑ Bernabe-Ramirez, Carolina; Velazquez, Ana I.; Olazagasti, Coral; Bergerot, Cristiane Decat; Bergerot, Paulo Gustavo; Soto-Perez-de-Celis, Enrique; Duma, Narjust (November 2020). "The HOLA COVID-19 Study: An International Effort to Determine How COVID-19 Has Impacted Oncology Practices in Latin America". Cancer Cell. 38 (5): 605–608. doi: 10.1016/j.ccell.2020.10.013 . PMC   7553055 . PMID   33098754.
  14. ↑ Schmidt, Andrew L.; Bakouny, Ziad; Bhalla, Sheena; Steinharter, John A.; Tremblay, Douglas A.; Awad, Mark M.; Kessler, Alaina J.; Haddad, Robert I.; Evans, Michelle; Busser, Fiona; Wotman, Michael; Curran, Catherine R.; Zimmerman, Brittney S.; Bouchard, Gabrielle; Jun, Tomi; Nuzzo, Pier V.; Qin, Qian; Hirsch, Laure; Feld, Jonathan; Kelleher, Kaitlin M.; Seidman, Danielle; Huang, Hsin-Hui; Anderson-Keightly, Heather M.; Abou Alaiwi, Sarah; Rosenbloom, Talia D.; Stewart, Penina S.; Galsky, Matthew D.; Choueiri, Toni K.; Doroshow, Deborah B. (December 2020). "Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study". Cancer Cell. 38 (6): 769–770. doi: 10.1016/j.ccell.2020.10.023 . PMC   7609043 . PMID   33176161.
  15. ↑ "Announcing the Rising Black Scientists Awards". www.cell.com.
  16. ↑ Sweet, Deborah J. (January 2021). "New at Cell Press: The Inclusion and Diversity Statement". Cell. 184 (1): 1–2. doi: 10.1016/j.cell.2020.12.019 . PMID   33417857.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.